生殖支原体gyrA突变及其对莫西沙星治疗失败的影响:是时候开发下一代耐药指导治疗了
研究分析了411例生殖支原体感染患者的parC和gyrA基因突变,其中194例接受莫西沙星治疗。携带parC S83I和gyrA双突变的感染较单一parC S83I突变者莫西沙星治疗失败率更高(81.2% vs 45.8%,P = .047),合并535例的汇总分析显示双突变者失败率80.6% vs 43.2%(P = .0027)。作者提出应将gyrA纳入下一代耐药指导治疗策略。
要点
- 生殖支原体parC S83I和gyrA双突变者莫西沙星治疗失败率较单一parC S83I突变者升高(81.2% vs 45.8%,P = .047)。
- 合并535例的汇总分析显示双突变者失败率80.6% vs 43.2%(P = .0027),提示叠加效应。
- 作者建议在澳大拉西亚地区将gyrA作为未来耐药检测的靶点,并提出了纳入parC和gyrA检测的下一代耐药指导治疗策略。
核心结论
- 与单一parC S83I突变相比,parC/gyrA双突变的生殖支原体感染导致莫西沙星治疗失败的可能性翻倍。
- 尽管抗菌药物耐药性在全球存在地区差异,这些数据提示在澳大拉西亚地区应考虑将gyrA作为未来耐药检测的靶点。
- 作者提出了纳入parC和gyrA检测的下一代耐药指导治疗策略。
研究设计与样本
- 研究分析了411例接受生殖支原体感染治疗的患者样本(男女均有),样本来自墨尔本性健康中心,时间为2019年3月至2020年2月,采用Sanger测序检测gyrA和parC。
- 对194例接受莫西沙星治疗的患者,分析了单核苷酸多态性(SNP)与微生物学治疗结局之间的关联。
- 另对535例的较大人群进行了汇总分析。
主要发现
- 最常见的parC SNP为G248T/S83I,占样本的21.1%,其次为D87N,占2.3%。
- 最常见的gyrA SNP为G285A/M95I,占7.1%。
- parC/gyrA双SNP见于8.6%的病例;携带parC G248T/S83I SNP的感染中,有三分之一同时存在gyrA M95I SNP。
- gyrA中的SNP与parC S83I变异同时出现。
- 在本研究194例分析中,parC S83I/gyrA双SNP患者的治疗失败率高于单一S83I SNP感染者(81.2% vs 45.8%,P = .047)。
关键数值与推荐
- parC G248T/S83I占样本的21.1%,D87N占2.3%,gyrA G285A/M95I占7.1%,parC/gyrA双SNP占8.6%。
- 194例分析中,parC S83I/gyrA双SNP者莫西沙星治疗失败率为81.2%,单一S83I SNP者为45.8%(P = .047)。
- 535例汇总分析中,双SNP者治疗失败率为80.6%,单一S83I SNP者为43.2%(P = .0027)。
临床怎么用
- 作者提出应开发纳入parC和gyrA检测的下一代耐药指导治疗策略。
- 作者认为在澳大拉西亚地区应考虑将gyrA作为未来耐药检测的靶点。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although single nucleotide polymorphisms (SNPs) in Mycoplasma genitalium parC contribute to fluoroquinolone treatment failure, data are limited for the homologous gene, gyrA. This study investigated the prevalence of gyrA SNPs and their contribution to fluoroquinolone failure. METHODS: Samples from 411 patients (male and female) undergoing treatment for M. genitalium infection (Melbourne Sexual Health Centre, March 2019-February 2020) were analyzed by Sanger sequencing (gyrA and parC). For patients treated with moxifloxacin (n = 194), the association between SNPs and microbiologic treatment outcome was analyzed. RESULTS: The most common parC SNP was G248T/S83I (21.1% of samples), followed by D87N (2.3%). The most common gyrA SNP was G285A/M95I (7.1%). Dual parC/gyrA SNPs were found in 8.6% of cases. One third of infections harboring parC G248T/S83I SNP had a concurrent SNP in gyrA conferring M95I. SNPs in gyrA cooccurred with parC S83I variations. Treatment failure was higher in patients with parC S83I/gyrA dual SNPs when compared with infections with single S83I SNP alone from analysis of (1) 194 cases in this study (81.2% vs 45.8%, P = .047), and (2) pooled analysis of a larger population of 535 cases (80.6% vs 43.2%; P = .0027), indicating a strong additive effect. CONCLUSIONS: Compared with parC S83I SNP alone, M. genitalium infections with dual mutations affecting parC/gyrA had twice the likelihood of failing moxifloxacin. Although antimicrobial resistance varies by region globally, these data indicate that gyrA should be considered as a target for future resistance assays in Australasia. We propose a strategy for the next generation of resistance-guided therapy incorporating parC and gyrA testing.
引用
- Murray GL, Plummer EL, Bodiyabadu K, et al. gyrA Mutations in Mycoplasma genitalium and Their Contribution to Moxifloxacin Failure: Time for the Next Generation of Resistance-Guided Therapy. Clin Infect Dis. 2023. PMID: 36722416. doi:10.1093/cid/ciad057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。